Chlamydia Infection Diagnostics And Therapeutics Industry Expansion Forecast Showing Market Size of $1.98 Billion by 2030 at 5.6% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Chlamydia Infection Diagnostics And Therapeutics Market Over The Period 2026–2030?
The chlamydia infection diagnostics and therapeutics market size has experienced strong growth in recent years. This market is projected to expand from $1.51 billion in 2025 to $1.59 billion in 2026, at a compound annual growth rate (CAGR) of 5.8%. Its historical growth can be attributed to several factors including the rising prevalence of sexually transmitted infections, the expansion of public health screening initiatives, the availability of effective antibiotic therapies, increasing awareness of reproductive health, and the growth in diagnostic laboratory infrastructure.
The chlamydia infection diagnostics and therapeutics market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $1.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this growth during the projection period include the wider acceptance of advanced Nucleic Acid Amplification Test (NAAT) technologies, increased funding for sexual health initiatives, the development of at-home diagnostic options, a stronger emphasis on antimicrobial stewardship, and the rising need for combined diagnostic and therapeutic platforms. Key trends anticipated for the forecast timeframe encompass the increasing utilization of molecular diagnostic tests, a surge in the deployment of rapid point-of-care diagnostics, a heightened inclination towards integrated diagnostic and treatment strategies, the broadening scope of antibiotic resistance surveillance, and a reinforced commitment to early diagnosis and screening efforts.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18295&type=smp
Which Major Factors Are Driving The Expansion Of The Chlamydia Infection Diagnostics And Therapeutics Market?
The increasing occurrence of sexually transmitted infections is anticipated to boost the expansion of the chlamydia infection diagnostics and therapeutics market in the coming years. Sexually transmitted infections are diseases typically transmitted through sexual contact, including vaginal, anal, or oral sex. The surge in sexually transmitted infections (STIs) stems from inconsistent or improper use of barrier methods, a lack of understanding and education concerning safe sex practices, evolving travel and migration patterns, and potentially reduced public health funding for prevention programs. Chlamydia infection diagnostics and therapeutics play a crucial role in managing sexually transmitted infections, ensuring early detection and effective treatment to avert complications and transmission. For instance, in October 2025, according to the Minority HIV/AIDS Fund (MHAF), an US-based government agency, an estimated 39.9 million individuals worldwide were living with HIV in 2023, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the escalating global incidence of sexually transmitted infections is propelling the growth of the chlamydia infection diagnostics and therapeutics market.
How Is The Chlamydia Infection Diagnostics And Therapeutics Market Divided Into Its Major Segments?
The chlamydia infection diagnostics and therapeutics market covered in this report is segmented –
1) By Type: Nucleic Acid Amplification Tests (NAATS), Direct Fluorescent Tests, Macrolides, Quinolones, Sulfonamides, Tetracycline, Aminopenicillins
2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection
3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nucleic Acid Amplification Tests (NAATS): PCR-Based Tests, LAMP-Based Tests
2) By Direct Fluorescent Tests: Direct Fluorescent Antibody Staining, Direct Fluorescent In-Situ Hybridization
3) By Macrolides: Azithromycin, Erythromycin
4) By Quinolones: Ciprofloxacin, Ofloxacin
5) By Sulfonamides: Sulfamethoxazole, Trimethoprim-Sulfamethoxazole
6) By Tetracycline: Doxycycline, Tetracycline
7) By Aminopenicillins: Amoxicillin, Ampicillin
What Industry Trends Are Redefining The Chlamydia Infection Diagnostics And Therapeutics Market?
Leading companies in the chlamydia market are concentrating on creating innovative solutions, such as the expansion of Point-of-Care Molecular Diagnostics, to achieve faster, more accurate onsite detection and improve timely treatment results. Point-of-care molecular diagnostics expansion denotes the broader implementation of rapid, immediate molecular tests that allow for the detection of infections like chlamydia without depending on central laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, secured FDA 510(k) clearance along with a CLIA waiver for its cobas liat molecular tests, which are engineered to diagnose sexually transmitted infections (STIs) directly at the point of care. These tests feature multiplex assay panels capable of detecting and differentiating multiple STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample, with results available in 20 minutes or less.
Who Are The Prominent Organizations Shaping The Chlamydia Infection Diagnostics And Therapeutics Market?
Major companies operating in the chlamydia infection diagnostics and therapeutics market are F. Hoffman La-Roche Ltd, Merck & Co. Inc., AbbVie Inc, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca, Abbott Laboratory, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Danaher Corporation, Gilead Sciences, Siemens Healthineers, Becton Dickinson and Company, Accelerate Diagnostics, Hologic Inc., Biomerieux, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin SpA, Luminex Corporation, Meridian Bioscience, Trinity Biotech Plc, Copan Diagnostics, Hain Lifescience GmbH
Read the full chlamydia infection diagnostics and therapeutics market report here:
Which Region Currently Holds The Largest Share Of The Chlamydia Infection Diagnostics And Therapeutics Market?
North America was the largest region in the chlamydia infection diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Chlamydia Infection Diagnostics And Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18295&type=smp
Browse Through More Reports Similar to the Global Chlamydia Infection Diagnostics And Therapeutics Market 2026, By The Business Research Company
Chlamydia Infection Diagnostics And Therapeutics Global Market Report
Chlamydia Trachomatis Ct And Neisseria Gonorrhoeae Ng Testing Global Market Report
Chlamydia Infection Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
